Stock Detail
Videos
NeurAxis, Inc. (NRXS) Company Webcast
NeurAxis, Inc., (NYSE American: NRXS) is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. This company webcast was recorded during the Lytham Partners 2026 Investor Healthcare...
NeurAxis (NRXS) Fireside Chat
NeurAxis, Inc. (NYSE American: NRXS) is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. This fireside chat was recorded during the Lytham Partners Fall 2025 Investor Conference.
NeurAxis (NRXS) Company Webcast
NeurAxis, Inc. (NYSE American: NRXS) is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. This company webcast was recorded during the Lytham Partners Spring 2025 Investor...
News
NeurAxis to Host Fourth Quarter and Full Year 2025 Results and Business Update Call on Thursday, March 19, 2026
CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will...
NeurAxis Achieves Major Milestone with AMA Category I CPT® Code Now in Effect, Establishing a Permanent Reimbursement Pathway
The new CPT code reflects the latest efficacious medical care available to patients, facilitating adoption and utilization.The assignment of a Category I CPT® code demonstrates a strong message to payers, both commercial and government, that there is now a path...
NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives
Total national coverage footprint for PENFS increases to roughly 100 million covered livesCARMEL, Ind., Dec. 19, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation...